Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

"We understand from Mylan NV's press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to detected trace amounts of impurity...," Solara Active Pharma Sciences in a filing to BSE.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news